Compare SPB & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPB | ARDX |
|---|---|---|
| Founded | 1906 | 2007 |
| Country | United States | United States |
| Employees | N/A | 489 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | 1994 | 2014 |
| Metric | SPB | ARDX |
|---|---|---|
| Price | $74.11 | $5.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $82.40 | $15.14 |
| AVG Volume (30 Days) | 302.0K | ★ 3.1M |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.70% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.21 | N/A |
| Revenue | ★ $3,802,100,000.00 | $2,607,000.00 |
| Revenue This Year | $1.78 | $38.22 |
| Revenue Next Year | $1.85 | $33.85 |
| P/E Ratio | $57.60 | ★ N/A |
| Revenue Growth | ★ 20.86 | N/A |
| 52 Week Low | $49.99 | $3.50 |
| 52 Week High | $80.42 | $8.40 |
| Indicator | SPB | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 50.58 | 31.37 |
| Support Level | $73.99 | $4.81 |
| Resistance Level | $80.42 | $5.34 |
| Average True Range (ATR) | 2.26 | 0.24 |
| MACD | -0.71 | -0.05 |
| Stochastic Oscillator | 62.69 | 18.36 |
Spectrum Brands Holdings Inc is consumer products and home essentials company. The company is a supplier of consumer batteries, residential locksets, residential builders' hardware, grooming products and personal care products. The company manages the businesses in product-focused segments; Home and Personal Care, global Pet Care, and Home and Garden. The Company manufactures, markets and distributes its products globally in the North America, Europe, Middle East & Africa, Latin America, and Asia-Pacific.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.